The injectable drug Ozempic is shown on July 1, 2023, in Houston. AP Photo/David J. Phillip, File
|Updated:
Canada has approved Ozempic to reduce the risk of kidney decline and cardiovascular death in patients with Type 2 diabetes.
Ozempic is the brand name of an injectable form of semaglutide, which is a glucagon-like peptide-1 hormone. It was first approved in Canada as a diabetes medication because it reduces blood sugar. It has previously been approved as a weight loss drug under the brand name Wegovy for people with obesity, as it can reduce appetite.
Chandra Philip is a news reporter with the Canadian edition of The Epoch Times.
